By Svetlana Sytina
The Ukrainian Times
The Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (IEPOR) under the National Academy of Sciences of Ukraine (NASU), the Lithuania’s National Institute of Cancer and the Institute of Physiology under the National Academy of Sciences of Byelorussia have concluded a tripartite agreement about work on the joint project of the analysis of the efficacy of the action of antitumor vaccines upon tumor-afflicted mice. The project provides for the comparative analysis of effectiveness of autovaccines and xenogenic vaccines in mice with melanoma and lung carcinoma.
According to Dr. Vasily Chekhun, IEPOR director and NASU member, signing of the cooperation agreement is a decisive step forward in cancer biotherapy because today the so-called gold standards of treatment satisfy neither clinics nor patients.
Iosif Zalutskiy, director of the Byelorussian Institute of Physiology, pointed out that a quest for the therapies of cancer in cooperation with Ukrainian and Lithuanian colleagues commenced as recently as the 1980s-1990s.
At present, there is no method of treatment that can be 100% efficacious against cancer. Dispiritingly, the three whales of modern oncology – surgery, chemotherapy and radiotherapy – do not produce a desired result, according to Dr. Eduardas Aleknavichyus, director of the Lithuania’s Institute of Cancer and project coordinator. That is why, from his point of view, it is necessary to quest for new biological methods and new lines of approach to the problem. Using the vaccines may be an improvement over the previous results of treatment.
Within the framework of the cooperation agreement, scientists of the three institutes will conduct joint research, exchange experts and solicit European foundations for money to continue work. Not only do the biotherapies have the potential to save millions of lives but the institutes that own them could make investors very rich.
No comments:
Post a Comment